What is the recommended management and follow‑up for central serous retinopathy in a middle‑aged adult male?

Management and Follow-up of Central Serous Retinopathy

For acute CSC (symptoms <3-4 months), observation is appropriate with monthly OCT monitoring, but for chronic CSC (persistent subretinal fluid >4-6 months with RPE changes), half-dose or half-fluence photodynamic therapy (PDT) guided by ICGA and FA is the definitive treatment of choice. 1

Initial Assessment and Classification

Distinguish between acute and chronic forms immediately:

• Acute CSC: Subretinal fluid present <3-4 months, typically isolated dome-shaped detachment on OCT, minimal RPE atrophy
• Chronic CSC: Persistent SRF >4-6 months with >1-2 disc areas of atrophic RPE changes, shallower detachment, extensive leakage on FA 1

Critical first step: Discontinue any corticosteroid use (systemic, topical, inhaled, or intranasal) before initiating treatment 1

Management Algorithm for Acute CSC

Observation is the standard approach for the first 3-4 months after diagnosis 1. The rationale: SRF resolves spontaneously in most acute cases, and 30% of even chronic cases show spontaneous resolution 1.

Follow-up schedule:

• OCT imaging every 4-6 weeks
• Monitor for complete SRF resolution
• Assess for development of chronic features

Consider early half-dose/half-fluence PDT in select acute cases when 1:

• Patient occupation demands immediate visual recovery (e.g., pilots—who face disqualification with recurrent disease) 2
• Bilateral involvement threatening functional vision
• Patient preference after informed discussion of risks/benefits

Management Algorithm for Chronic CSC

First-Line Treatment: Half-Dose or Half-Fluence PDT

Half-dose or half-fluence PDT guided by ICGA and FA is the only treatment with robust evidence for efficacy 1, 3. The PLACE, VICI, and SPECTRA trials established this as superior to all alternatives 1.

Treatment protocol 1:

1. Target hyperfluorescent areas on ICGA corresponding to focal leakage on FA and SRF on OCT
2. For multiple leakage areas: use large spot including all areas, or multifocal sequential spots starting with fovea
3. Half-dose: 3 mg/m² verteporfin (vs. standard 6 mg/m²)
4. Half-fluence: 25 J/cm² (vs. standard 50 J/cm²)

Expected outcomes:

• 67% complete SRF resolution at 7-8 months 1
• 78% resolution at 3 months 1
• Significant BCVA improvement and retinal sensitivity gains 1, 3
• Lower recurrence rates compared to other modalities 1

Second-Line Options (When PDT Unavailable)

Conventional argon laser photocoagulation may be used ONLY for 1:

• Focal extrafoveal leakage points (outside central macula)
• When PDT access is limited or cost-prohibitive
• Major caveat: Risk of paracentral scotoma, choroidal neovascularization, and does not address underlying choroidal dysfunction 1

Ineffective or Unproven Treatments

Mineralocorticoid receptor antagonists (eplerenone, spironolactone) showed disappointing results in high-quality RCTs 1:

• VICI trial: Only 16% complete SRF resolution with eplerenone vs. 30% with placebo at 12 months 1
• SPECTRA trial: Only 17% resolution with eplerenone vs. 78% with half-dose PDT 1
• Do not use as primary treatment; reserve only for cases where PDT is absolutely unavailable and laser inappropriate 1

Subthreshold micropulse laser: Inferior to PDT with only 29% long-term resolution vs. 67% with PDT 1. Evidence of efficacy is modest 1.

Management of Treatment Failures

If SRF persists after initial half-dose/half-fluence PDT 1:

1. Re-evaluate diagnosis using multimodal imaging (OCT, OCT-A, FA, ICGA, FAF) to exclude mimics
2. Screen for macular neovascularization (MNV) development—occurs in subset of chronic cases
3. Re-treat with PDT if persistent leakage on FA/ICGA without other diagnosis
4. Consider full-dose PDT if repeated half-dose treatments fail 1

Crossover data: 87% of patients who failed eplerenone achieved complete SRF resolution at 3 months after switching to half-dose PDT 1

Special Circumstance: CSC with Macular Neovascularization

Treat with combination therapy 1:

• Intravitreal anti-VEGF injections (ranibizumab, bevacizumab, or aflibercept)
• PLUS half-dose/half-fluence PDT
• OCT-A is valuable for early MNV detection 4

Follow-up Protocol

For patients under observation (acute CSC):

• OCT every 4-6 weeks until resolution
• If SRF persists >3-4 months, reclassify as chronic and initiate PDT

For patients treated with PDT:

• OCT at 6-8 weeks post-treatment to assess response 1
• If small residual SRF: Conservative follow-up at 1-3 months may be appropriate 1
• Long-term monitoring for recurrence (occurs in minority but less than with other treatments) 1

For chronic cases with complete resolution:

• Periodic monitoring as recurrence risk persists
• Patient education on symptom recognition

Critical Pitfalls to Avoid

1. Do not treat acute CSC prematurely: Most resolve spontaneously; unnecessary treatment exposes patients to risks
2. Do not use eplerenone/spironolactone as first-line: Large RCTs proved non-superiority to placebo 1
3. Do not apply conventional laser to central/juxtafoveal leaks: Risk of permanent scotoma 1
4. Do not miss concurrent MNV: Requires different treatment approach with anti-VEGF 1
5. Verteporfin shortage: Current global shortage complicates access to PDT; do not substitute with ineffective alternatives that expose patients to unnecessary risks 1, 3

Quality of Life Considerations

Chronic CSC significantly impairs vision-related quality of life even when BCVA appears preserved 1. Microperimetry shows retinal sensitivity improvements with PDT that may not be captured by BCVA alone 1, supporting treatment even in cases with seemingly adequate visual acuity. Middle-aged working adults face occupational impacts, particularly in visually demanding professions 2.